JP6290187B2 - 癌の処置のためのタンパク質の部位特異的標識及び標的送達 - Google Patents

癌の処置のためのタンパク質の部位特異的標識及び標的送達 Download PDF

Info

Publication number
JP6290187B2
JP6290187B2 JP2015511804A JP2015511804A JP6290187B2 JP 6290187 B2 JP6290187 B2 JP 6290187B2 JP 2015511804 A JP2015511804 A JP 2015511804A JP 2015511804 A JP2015511804 A JP 2015511804A JP 6290187 B2 JP6290187 B2 JP 6290187B2
Authority
JP
Japan
Prior art keywords
protein
annexin
pharmaceutical composition
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015511804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519339A5 (https=
JP2015519339A (ja
Inventor
クランツ，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015519339A publication Critical patent/JP2015519339A/ja
Publication of JP2015519339A5 publication Critical patent/JP2015519339A5/ja
Application granted granted Critical
Publication of JP6290187B2 publication Critical patent/JP6290187B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2015511804A 2012-05-11 2013-05-13 癌の処置のためのタンパク質の部位特異的標識及び標的送達 Expired - Fee Related JP6290187B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261688308P 2012-05-11 2012-05-11
US61/688,308 2012-05-11
US201261741984P 2012-08-01 2012-08-01
US61/741,984 2012-08-01
US201361848601P 2013-01-07 2013-01-07
US61/848,601 2013-01-07
US201361849034P 2013-01-17 2013-01-17
US61/849,034 2013-01-17
PCT/US2013/040823 WO2013170272A2 (en) 2012-05-11 2013-05-13 Site-specific labeling and targeted delivery of proteins for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2015519339A JP2015519339A (ja) 2015-07-09
JP2015519339A5 JP2015519339A5 (https=) 2016-07-07
JP6290187B2 true JP6290187B2 (ja) 2018-03-07

Family

ID=49551481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511804A Expired - Fee Related JP6290187B2 (ja) 2012-05-11 2013-05-13 癌の処置のためのタンパク質の部位特異的標識及び標的送達

Country Status (5)

Country Link
US (1) US9545449B2 (https=)
EP (1) EP2850201A4 (https=)
JP (1) JP6290187B2 (https=)
CA (1) CA2873112A1 (https=)
WO (1) WO2013170272A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
CN101784565B (zh) 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
BR112015008365A2 (pt) 2012-10-16 2017-07-04 Endocyte Inc composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
CA2951368A1 (en) 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
JP6772199B2 (ja) * 2015-08-11 2020-10-21 コヒレント バイオファーマ 多リガンド−薬物複合体及びその使用
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
KR20180090290A (ko) 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
US11690919B2 (en) 2017-01-17 2023-07-04 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
JP7590328B2 (ja) 2018-12-21 2024-11-26 レゲネロン ファーマシューティカルス，インコーポレーテッド ツブリシン及びタンパク質－ツブリシンコンジュゲート
US12527871B2 (en) 2019-06-05 2026-01-20 Boston Scientific Scimed, Inc. Click chemistry capturable platinum-based antineoplastic agents
US20230201365A1 (en) * 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
EP4366781A1 (en) * 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Checkpoint inhibitors conjugated to il-2, and uses thereof
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066490A (en) 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
AU745094B2 (en) 1997-06-13 2002-03-14 Gryphon Sciences Solid phase native chemical ligation of unprotected or N-terminal cysteine protected peptides in aqueous solution
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US20020164649A1 (en) 2000-10-25 2002-11-07 Rajendra Singh Mass tags for quantitative analysis
WO2002087497A2 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
WO2003087310A2 (en) 2002-04-04 2003-10-23 California Institute Of Technology Directed protein docking algorithm
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP1534269B1 (en) 2002-07-19 2013-10-30 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US20110002978A1 (en) * 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
AP2081A (en) 2004-06-18 2010-01-04 Ipf Pharmaceuticals Gmbh Oligomeric peptides and their use for the treatment of HIV infections
WO2007112362A2 (en) 2006-03-24 2007-10-04 The Regents Of The University Of California Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
ES2672526T3 (es) * 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
US8431521B2 (en) * 2008-10-03 2013-04-30 Advanced Proteome Therapeutics, Inc. Site-specific chemical modification of proteins at their N-termini, enabling the formation of homogeneous adducts
DK2437773T3 (en) * 2009-06-03 2017-02-06 Mosamedix Bv PROCEDURE FOR IMPROVING PHAGOCYTOSIS OF PHOSPHATIDYLSERINE-EXPOSING CELLS
EP2536287A4 (en) * 2010-02-18 2015-10-07 Advanced Proteome Therapeutics Inc SPECIFIC SITE SIZE OF PROTEINS USING CHEMICAL MODIFICATION TO PROMOTE PROTEIN CONJUGATE FORMATION, PROTEIN DIMER FORMATION, AND AGRAFTED PEPTIDES
EP2566334B1 (en) * 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
WO2011153250A2 (en) * 2010-06-01 2011-12-08 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives

Also Published As

Publication number Publication date
US9545449B2 (en) 2017-01-17
WO2013170272A2 (en) 2013-11-14
US20150202314A1 (en) 2015-07-23
EP2850201A2 (en) 2015-03-25
CA2873112A1 (en) 2013-11-14
EP2850201A4 (en) 2016-08-31
JP2015519339A (ja) 2015-07-09
WO2013170272A3 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
JP6290187B2 (ja) 癌の処置のためのタンパク質の部位特異的標識及び標的送達
Rahimizadeh et al. Albumin: an emerging opportunity in drug delivery
JP7490735B2 (ja) ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
JP2025066807A (ja) 生体直交型組成物
US10894813B2 (en) Methods of using therapeutic p53 peptides
JP6355563B2 (ja) Ｘｔｅｎ共役組成物およびそれを製造する方法
CN105934257B (zh) 用于含氮和羟基的药物的生物可逆引入基团
ES2349743T3 (es) Derivados de la il-21.
JP6426103B2 (ja) ｃ−Ｍｅｔタンパク質アゴニスト
JP7425606B2 (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
JP2009520040A (ja) 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
CN104666246A (zh) 口服生物利用的基于脂质的结构
CN102245636A (zh) 用于药物递送的依托泊苷和多柔比星结合物
Lim Site-specific bioconjugation and self-assembly technologies for multi-functional biologics: on the road to the clinic
WO2023077129A1 (en) Tetrazine conjugates for in vivo targeted delivery of a payload
JP2024512775A (ja) 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
WO2023077126A1 (en) Trans-cyclooctene conjugates
JP2021521270A (ja) 治療剤の制御放出用組成物
WO2017212494A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
WO2018183232A2 (en) Peptides and methods for targeted delivery to tumors
EP4704904A1 (en) Tetrazine-based targeting agents for in vivo delivery of a payload
HK40109540A (zh) 反式环辛烯缀合物
JP2025532958A (ja) ＥｐｈＡ２結合保留ペプチド及びそれを含む組成物
HK40108922A (zh) 用於有效载荷的体内靶向递送的四嗪缀合物
IL325021A (en) Glypican-3-targeting peptide compositions and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180207

R150 Certificate of patent or registration of utility model

Ref document number: 6290187

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees